HALIX started construction activities for the new facilityTuesday, July 3, 2018
On behalf of Droege Group, Dr. Ernest Droege, CEO of the company, and Dr. Hedda im Brahm-Droege, Member of Supervisory Board, started the ceremonial actions.
Dr. Harry Flore, CEO of HALIX, is proud to kick-start the construction activities for the new facility: “This is a milestone that creates a solid base for a bright future of HALIX.”, says Dr. Harry Flore.
HALIX is a contract development & manufacturing organization (CDMO) and licensed for clinical and commercial GMP contract manufacturing of biopharmaceuticals. We provide services to biopharmaceutical partners, enabling them to harvest on their research activities, and to enter and supply their markets with the most efficient use of resources. Our focus is GMP manufacturing of biologics, by manufacturing drug substance on eucaryotic cells, and by performing aseptic fill and finish and lyophilization services. Within the next years we are extending our scope of services for therapeutic proteins and viral vaccines.
Mr. Paul Dirkse, Alderman of the Municipality of Leiden, praised HALIX for settling in the Leiden Bio Science Park and therefore contributing to the continuous development of the area.
The Leiden Bio Science Park is the largest science cluster in the Netherlands and brings together Leiden University, Leiden University Medical Center (LUMC), and approximately 150 companies in close proximity. There is a lot of energy and expertise moving around between companies in the Bio Science Park. Being part of that is a great benefit for HALIX.
Founded in 2012 HALIX, a corporate venture and spin-off of HAL Allergy, is a contract development and manufacturing organization (CDMO), based in Leiden, the Netherlands. The company is licensed for the contract manufacturing of clinical and commercial medicines according to GMP standards. HALIX leverages advanced biopharmaceutical technologies and provides the full portfolio of pharmaceutical documentation of GMP production processes, as well as production of units which are required for clinical approval. HALIX, as an end-to-end service provider, will serve its customers the full range from the first development steps to start of commercial production after successful registration of products. More information is available on: www.halix.nl.
About Droege Group
Droege Group (founded in 1988) is an independent advisory and investment company under full family ownership. The company acts as a specialist for tailor-made transformation programs aiming to enhance corporate value. Droege Group combines its corporate family-run structure and capital strength into a family-equity business model. The group carries out direct investments with its own equity in corporate spin-offs and medium-sized companies in “special situations”. With the guiding principle “execution – following the rules of art”, the group is a pioneer in execution-oriented corporate development. Droege Group follows a focused investment strategy based on current megatrends (knowledge, connectivity, prevention, demography, specialization, future work, shopping 4.0). Enthusiasm for quality, innovation and speed determines the company’s actions. In recent years Droege Group has successfully positioned itself in domestic and international markets and operates in 30 countries. More information is available on www.droege-group.com.
Galapagos receives Fast Track designation from FDA for GLPG1972/S201086 in osteoarthritis
Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)
Pharming reports favourable conclusion from first investigator-initiated direct comparative real-world study of acute hereditary angioedema therapies